Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

This early-stage study tests a vaccine designed to train the immune system to attack cells with a specific mutation (mutant KRAS) that can lead to pancreatic cancer. The study enrolls 37 people at high risk due to family history or pancreatic abnormalities. The main goals are to …

This early-phase study tests a peptide vaccine designed to train the immune system to attack ALK-positive lung cancer cells. The goal is to prevent or delay resistance to standard targeted therapies. About 12 adults with advanced ALK+ non-small cell lung cancer who are stable on …

This study tests a new vaccine called PVX7 in 32 women with advanced cervical cancer who have finished their main treatment. The goal is to see if the vaccine is safe and can boost the body's immune response against the HPV virus that causes the cancer. Participants will receive …

This study tests the drug olaparib (a pill) in 20 people with advanced kidney cancer that has spread. To join, your tumor must have a specific gene mutation (like BAP-1 or BRCA). The goal is to see if the drug can shrink or stop tumor growth for at least 6 months. Participants mu…

This study tests giving chemotherapy and immunotherapy before standard surgery for head and neck cancer. The goal is to shrink tumors enough so that surgeons can do a less extensive operation, preserving speech, swallowing, and vision. About 75 adults with newly diagnosed, advanc…

This study tests a precise type of radiation called proton beam therapy for people with cancer that has spread to the spine and cannot be treated effectively with standard radiation. The goal is to see if this approach is feasible and safe. About 12 participants will receive the …

This study tests whether the drug nivolumab can be safely given after a half-matched bone marrow transplant to help prevent sarcoma from returning. It includes children and young adults (ages 1 to 50) with high-risk, recurrent, or hard-to-treat sarcomas. Researchers will monitor …

This early-phase study tests a vaccine designed to target a specific protein found in fibrolamellar carcinoma, a rare liver cancer. The vaccine is given together with two immunotherapy drugs (nivolumab and ipilimumab) to see if it is safe and can boost the body's immune response …

This study tests a two-step treatment plan for men with advanced prostate cancer that has stopped responding to standard hormone therapy. First, patients receive a combination of testosterone and an experimental drug called ZEN-3694, followed by a mix of enzalutamide and ZEN-3694…

This study tests whether giving three drugs (gemcitabine, cisplatin, and pembrolizumab) before and after surgery is safe and helps shrink bile duct cancers. About 27 adults with resectable biliary tract cancer will receive the treatment. Researchers will check how the immune syst…

This study tests a stem cell transplant using milder chemotherapy for people with certain immune deficiencies or bone marrow failure. The goal is to see if donor cells can take over the bone marrow and restore a working immune system. About 27 participants will be enrolled, and t…

This study tests whether giving the drug enoblituzumab for 12 weeks before prostate removal surgery can help prevent cancer from coming back in men with high-risk localized prostate cancer. About 219 men will be randomly assigned to receive either enoblituzumab or standard care. …

This study tests whether an early PET scan can help doctors personalize chemotherapy and immunotherapy for people with stage 2 or 3 triple negative breast cancer. About 30 participants will receive a combination of drugs, and those whose tumors shrink quickly may avoid extra chem…

This study tests whether two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal…

This early-stage trial tests whether adding the immunotherapy drug retifanlimab to standard treatments (carmustine wafers, radiation, and possibly temozolomide) is safe and helps people with newly diagnosed glioblastoma, an aggressive brain cancer. About 50 adults who have alread…

This study is for people with metastatic pancreatic cancer that has spread and hasn't been treated yet. It tests a two-step approach: first, a low-dose mix of five chemotherapy drugs, then long-term maintenance with two targeted drugs (olaparib and pembrolizumab). The goal is to …

This study is for people with very high-risk solid tumors that have come back or spread. It tests a bone marrow transplant from a partially matched family donor, using milder chemotherapy and a shorter course of immune-suppressing drugs. The goal is to see if this approach is saf…

This study tests whether a 12-week exercise program can reduce the number of cancer cells in the blood of men with advanced prostate cancer. Twenty men on hormone therapy will exercise regularly and have their blood tested before, during, and after the program. The goal is to see…

This study tests whether giving two drugs (pembrolizumab and IO102-103) before surgery is safe and effective for people with head and neck cancer. About 30 adults with removable tumors will receive the drug combination, then have surgery. Researchers will monitor side effects and…

This study is for children, teens, and young adults (up to age 39) with sarcoma that has spread to a few other places in the body. The goal is to see if giving radiation to those spread spots, along with standard treatment, can help them live longer without the cancer getting wor…

This study tests two different cancer vaccines (GVAX and a KRAS peptide vaccine) given with two immunotherapy drugs for people with pancreatic cancer that can be surgically removed. The goal is to find the safest dose and see if the treatment helps the immune system fight the can…

This study is for men with advanced prostate cancer that has stopped responding to standard hormone therapy but who are not yet in pain. It compares two treatments: taking the drug enzalutamide alone versus taking it along with cycles of high-dose testosterone. The goal is to see…

This study tests a new way to treat advanced prostate cancer that has stopped responding to standard hormone therapy. About 50 men with no pain from their cancer will receive a sequence of two drug combinations: first, a high dose of testosterone with another drug, then a differe…

This study tests whether two immunotherapy drugs, cemiplimab alone or combined with fianlimab, can eliminate tumors in older adults (age 70+) or those unfit for surgery with a specific genetic type of colorectal cancer (MSI-H). The goal is to achieve a complete response, meaning …

This trial provides a single patient with advanced prostate cancer access to an experimental treatment called X-PACT, which combines a light-sensitive drug (methoxsalen) with X-rays to kill tumor cells and possibly trigger an immune response. The patient has no other standard tre…

This study tests whether a lower dose of total body irradiation (200 cGy) before a bone marrow transplant works as well as the standard higher dose (400 cGy) for people with acute leukemia. The goal is to see if the lower dose reduces serious side effects like graft-versus-host d…

This study tests whether adding dexamethasone or metronidazole can make abiraterone work again for men with advanced prostate cancer that has stopped responding to treatment. About 58 men will receive one of these add-on drugs alongside their current therapy. The goal is to lower…

This early-phase study tests whether adding the drug momelotinib to standard treatment (azacitidine) can better control rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take the combination for up to 24 months. The go…

This early-phase study tests a combination of a vaccine targeting mutant KRAS proteins and two immunotherapy drugs (balstilimab and botensilimab) in adults with advanced colorectal or pancreatic cancer that has not responded to first-line chemotherapy. The goal is to see if the t…

This study tests a new way to deliver internal radiation (brachytherapy) for men with early-stage prostate cancer. By using a special PET scan to find only the aggressive parts of the tumor, doctors hope to treat just those areas and leave healthy tissue alone, which may reduce s…

This study tests whether the drug nivolumab, alone or combined with relatlimab or ipilimumab, can shrink or control advanced basal cell skin cancer that cannot be removed by surgery or has spread. About 57 adults with this condition will receive treatment. The goal is to see how …

This study tests a new drug (NC410) added to standard chemotherapy (FOLFIRINOX) and two immunotherapy drugs (nivolumab with or without ipilimumab) for people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and find any unexpect…

This study tests a new drug combination for people with advanced fibrolamellar carcinoma, a rare liver cancer. The drugs are DRP-104 (a glutamine blocker) and durvalumab (an immunotherapy). The goal is to see if the combination is safe and can shrink tumors. About 27 participants…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check safety …

This study tests if a short course of proton therapy (5 sessions) before surgery for soft tissue sarcoma in the arms, legs, or trunk is safe and effective. About 40 adults will receive the therapy and then have standard surgery. Researchers will track wound healing problems and q…

This study tests a new treatment approach for men with metastatic prostate cancer that has stopped responding to standard hormone therapy. It alternates high-dose testosterone with a drug called darolutamide to see if this cycling can keep the cancer under control longer. About 6…

This early-stage study tests a personalized cancer vaccine (mBTCvax) combined with two immunotherapy drugs (durvalumab and tremelimumab) in 25 adults with advanced biliary tract cancer. The goal is to see if the combination is safe and can strengthen the body's immune response ag…

This study tests a combination of two cancer drugs, enfortumab vedotin and pembrolizumab, in 20 people with high-grade upper tract urothelial cancer (a rare cancer of the kidney and ureter). Participants are those who cannot or choose not to have standard surgery to remove the ki…

This study tests a new treatment for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The treatment combines a hormone therapy (testosterone) with a radioactive drug (radium-223) to try to slow cancer growth. About 47 men will recei…

This study tests whether giving immunotherapy (with or without chemo) before standard treatments can allow doctors to use less intense, gentler therapy while still curing the cancer. About 32 adults with advanced HPV-related head and neck cancer will receive the drugs first, then…

This study is for people with kidney cancer who cannot have surgery or other local treatments. It uses a precise type of radiation called proton beam therapy to target the tumor while aiming to protect the kidney. Researchers will track how well the kidney works after treatment a…

This early study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. The main goal is to check if the drug is safe and how it moves through the body, …

This study tests whether using MRI to guide brachytherapy (internal radiation) for gynecologic cancers like cervical or uterine cancer can better target tumors and reduce radiation to nearby organs like the bladder and rectum. About 54 adults who are already eligible for standard…

This study is creating a registry to collect detailed information on children and young adults (up to age 26) who receive radiation therapy for sarcoma or brain tumors. The goal is to track their health over time, including survival and side effects, to better understand the long…

This study is looking at 40 adults with chordoma, a rare tumor of the spine or skull base. Researchers want to see if a simple blood test (ctDNA) and special scans (radiomics) can predict how well the tumor responds to radiation therapy before surgery. The goal is to find better …

This study is for people with breast cancer that has spread to the lining of the brain or spinal cord, a condition called leptomeningeal disease. The goal is to collect samples and health information to better understand this rare and serious complication. Researchers hope to spe…

This study collects blood, tumor, and other tissue samples from up to 1,250 people with head and neck, lung, or gastrointestinal cancers. The goal is to learn how the immune system changes during cancer treatments that affect immunity. Participants donate samples and fill out que…

This early-phase trial is for people with a specific type of brain tumor (glioma) that has a BRAF-V600E mutation and has not responded to prior treatments. The study aims to see if tumor DNA can be detected in blood and spinal fluid samples before and during treatment with the dr…

This study tests a new type of MRI that may help doctors see the most active parts of a brain tumor. The goal is to use this information to aim radiation therapy more precisely. About 20 adults with glioblastoma will take part to see if this approach improves treatment response.

This observational study will use SPECT imaging to measure how radiopharmaceutical therapies distribute in the body of 80 patients with advanced prostate or other cancers. The goal is to improve dosing calculations to make treatment safer and more effective. No new drugs are give…

This study looks at ways to increase the number of men with metastatic prostate cancer who receive next-generation sequencing (NGS) testing. The researchers believe that by addressing obstacles for both doctors and patients, more men will get this important genetic test. About 25…

This study looks at whether a blood test (liquid biopsy) can find genetic changes in tumors to help doctors pick the best treatment. About 150 people with solid cancers will give blood samples before and during treatment. The goal is to see if these tests can guide therapy decisi…

This study looks at whether giving cancer patients more personalized help (high-intensity navigation) makes them more likely to join a clinical trial compared to standard help (low-intensity navigation). About 90 adults with prostate or kidney cancer will take part. The goal is t…